Business Context and Reporting Period
Company: Dr. Reddy's Laboratories Limited (DRL)
Filing Type: Form 6-K (Quarterly Report)
Reporting Period: Quarter and Nine Months ended December 31, 2015
Business Overview: DRL is a leading India-based pharmaceutical company operating through three primary segments: Global Generics, Pharmaceutical Services and Active Ingredients (PSAI), and Proprietary Products. The company manufactures and markets active pharmaceutical ingredients (APIs), generics, biosimilars, and differentiated formulations globally.
Key Financial Metrics
Note: All figures in Indian Rupees (Rs.) are in millions unless otherwise stated. U.S. Dollar translations are provided for convenience at the rate of Rs. 66.19 = U.S.$1.00.
Income Statement Highlights (Nine Months Ended Dec 31, 2015)
| Metric | 2015 (Rs. Mn) | 2015 (U.S.$ Mn) | 2014 (Rs. Mn) |
|---|---|---|---|
| Revenues | 117,146 | 1,770 | 109,485 |
| Gross Profit | 71,005 | 1,073 | 64,182 |
| Gross Margin | 60.6% | - | 58.6% |
| Operating Profit | 24,547 | 371 | 20,166 |
| Net Profit | 19,267 | 291 | 16,990 |
| Effective Tax Rate | 21.9% | - | 23.6% |
Balance Sheet Highlights (As of Dec 31, 2015)
| Metric | Dec 31, 2015 (Rs. Mn) | Mar 31, 2015 (Rs. Mn) |
|---|---|---|
| Cash and Cash Equivalents | 5,903 | 5,394 |
| Total Current Assets | 119,327 | 119,838 |
| Total Assets | 207,882 | 194,762 |
| Short-term Borrowings | 23,004 | 21,857 |
| Long-term Borrowings | 10,692 | 14,307 |
| Total Liabilities | 79,201 | 83,460 |
| Total Equity | 128,681 | 111,302 |
Cash Flow (Nine Months Ended Dec 31, 2015)
- Net Cash from Operating Activities: Rs. 31,991 million (U.S.$ 483 million)
- Net Cash Used in Investing Activities: Rs. (15,266) million (U.S.$ (231) million)
- Net Cash Used in Financing Activities: Rs. (15,838) million (U.S.$ (239) million)
Material Changes vs. Prior Period
- Revenue Growth: Consolidated revenues increased 7% to Rs. 117,146 million for the nine months ended Dec 31, 2015, compared to Rs. 109,485 million in the prior year.
- Global Generics: Revenue grew 10% to Rs. 97,287 million, driven by new product launches (e.g., esomeprazole, memantine) and volume growth in North America and India.
- PSAI: Revenue declined 8% to Rs. 16,614 million due to lower sales volumes and prices of active pharmaceutical ingredients.
- Profitability: Net profit increased 13% to Rs. 19,267 million. Gross margin improved to 60.6% from 58.6%, aided by a favorable product mix in the Global Generics segment.
- Debt Reduction: Long-term borrowings decreased significantly from Rs. 14,307 million to Rs. 10,692 million, primarily due to the full repayment of foreign currency borrowings by the Swiss and U.K. subsidiaries.
- Foreign Exchange Impact: The company recorded a foreign exchange loss of Rs. 776 million related to the translation of monetary assets and liabilities of its Venezuelan subsidiary due to currency devaluation.
Guidance, Outlook, Risks, and Unusual Items
Management Commentary and Outlook
Management highlighted strong performance in the Global Generics segment, particularly in North America and India. The company continues to invest in R&D for complex formulations and biosimilars. No specific forward-looking financial guidance was provided in this filing.
Key Risks and Contingencies
- Venezuela Operations: Deteriorating economic conditions and currency devaluation in Venezuela pose significant risks. The company recorded substantial foreign exchange losses and faces uncertainty regarding the realization of monetary assets at preferential exchange rates.
- Regulatory Actions (U.S. FDA): The company received a warning letter on November 5, 2015, regarding cGMP deviations at API facilities in Srikakulam and Miryalaguda, and an oncology formulation facility in Duvvada. While production is not currently restricted, failure to resolve issues could lead to product refusal or withholding of new approvals.
- Legal Litigation:
- Patent Litigation: Settled litigation with Novartis regarding Reclast and Zometa, agreeing to a one-time payment of Rs. 430 million (U.S.$ 6.5 million) for a license.
- Antitrust: Ongoing investigations and class actions regarding pricing practices and patent settlements (e.g., Namenda, Nexium).
- Environmental: Pending proceedings regarding land and water pollution in India, though the company believes additional liability is remote.
Unusual Items
- Acquisitions:
- Acquired a select portfolio of products from UCB (India, Nepal, Sri Lanka, Maldives) for Rs. 8,000 million, closed in June 2015.
- Purchased intellectual property rights for fondaparinux sodium from Alchemia for Rs. 1,158 million.
- Purchased rights to Xeglyze Lotion from Hatchtech for Rs. 947 million (including milestones).
- Impairment: No new goodwill impairment was recorded in the current period; historical impairment related to the German subsidiary (betapharm) remains on the books.
Investor Verification Checklist
- Venezuela Exposure: Verify the current status of the Venezuelan subsidiary's ability to repatriate funds and the potential for further foreign exchange losses given the SIMADI exchange rate volatility.
- FDA Compliance: Monitor the company's progress in addressing the cGMP deviations cited in the November 2015 warning letter to ensure no future product import restrictions.
- Debt Profile: Confirm the interest rate exposure on the remaining short-term borrowings (primarily packing credits) and the repayment schedule for the remaining long-term U.S. dollar loan.
- Legal Settlements: Track the financial impact of the Novartis settlement and the status of ongoing antitrust investigations in the U.S.
- Segment Mix: Assess the sustainability of the revenue growth in Global Generics versus the decline in PSAI, particularly regarding pricing pressures in the U.S. generic market.